Ovid Therapeutics (OVID) Short-term Investments (2018 - 2026)

Ovid Therapeutics has reported Short-term Investments for 8 years, with the latest figure at $61.5 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 181.14% year-over-year to $61.5 million; the trailing twelve-month figure through Mar 2026 stood at $61.5 million (up 181.14% YoY), and the FY2025 full-year result was $56.5 million, up 110.96% from the prior year.
• Short-term Investments for Q1 2026 stood at $61.5 million, up from $56.5 million in the prior quarter.
• The five-year high for Short-term Investments was $84.1 million in Q4 2022, with the low at $5.0 million in Q3 2025.
• Historically, Short-term Investments has averaged $48.0 million across 5 years, with a median of $51.2 million in 2023.
• Annual changes were most pronounced in 2025 — Short-term Investments plunged 89.53% — and 2026, when it soared 181.14%.
• Ovid Therapeutics' Short-term Investments stood at $84.1 million in 2022, then retreated by 6.35% to $78.8 million in 2023, then slumped by 66.02% to $26.8 million in 2024, then soared by 110.96% to $56.5 million in 2025, then advanced by 8.81% to $61.5 million in 2026.
• The last three Short-term Investments figures came in at $61.5 million (Q1 2026), $56.5 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.